Health ❯ Healthcare ❯ Patient Care

Oncology

Survival Rates Cancer Treatment Chemotherapy Metastatic Cancer Treatment Outcomes Medication Access Melanoma Leukemia Tumor Removal Advanced Cancer Metastatic Breast Cancer Urologic Oncology Advanced Melanoma Neurosurgery Recurrent Cancer Palliative Care Treatment Experiences Exercise Programs Medications Tumor Treatment Oncohematology Hospital Facilities Dietary Management in Oncology Hormone Receptor Positive Breast Cancer Bladder Cancer Management Oncology Unit Contamination Child Health Delays in Treatment Aggressive Lymphoma Cancer Diagnosis Cancer Support Support Systems Support Networks Bone Marrow Transplant Muscle-Invasive Bladder Cancer Acute Lymphoblastic Leukemia Cancer Cachexia Combination Therapy Prostate Cancer Treatment Surgical Procedures Relapsed/Refractory Multiple Myeloma Breast Cancer Treatment Communication Strategies Cancer Patient Support Advanced Breast Cancer Solid Tumors Relapsed Multiple Myeloma Access to Treatment Advanced Lung Cancer Tumor Markers Personalized Medicine Blood Components Childhood Cancer Precision Medicine Patient Experiences Cancer Therapies Radiology

PROTEXI Vaccine Redirects COVID‑19 Immune Memory to Target Tumors

A peer‑reviewed preclinical study reports stronger tumor‑specific T‑cell responses and has prompted plans for a first‑in‑human sarcoma trial.

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Most Detailed Prostate Cancer Cell Atlas Yet Charts Earliest Disease Signals

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Quitting After Cancer Diagnosis Linked to Higher Two-Year Survival, JNCCN Study Finds

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Next-Generation CAR-T Therapies Deliver Remission in T-Cell Cancers and Extend Survival in Gastric and Brain Tumors